NeurologyLive® Friday 5 — December 20, 2024

Author(s):

Key Takeaways

Recognition and advocacy are crucial in multiple sclerosis care, with nurses playing a pivotal role in patient support and mentorship.
Stem cell therapies hold potential for restoring neural function in epilepsy, offering hope for regenerative treatment approaches.
Women's neurology is emerging as a subspecialty, focusing on brain health issues specific to half the world's population.
Innovative procedures like stereo electroencephalography are advancing epilepsy surgery, aiding in precise localization of epileptic foci.
New FDA-approved agents for NMOSD management can reduce relapse and hospitalization rates, enhancing patient outcomes.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 20, 2024.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Using the PERC Database to Gather Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of experts talked about 2 studies presented at AES 2024 that used the Pediatric Epilepsy Research Consortium genetics database to study factors influencing latency in genetic testing and drug-resistant epilepsy. [WATCH TIME: 5 minutes]

2: Addressing Disparities and Improving Care Through Pediatric Epilepsy Research: Adam Numis, MD; Laura Kirkpatrick, MD

At AES 2024, a duo of pediatric epilepsy specialists highlighted a Pediatric Epilepsy Research Consortium review on the need for standardized socio-demographic data and better follow-up for at-risk infants. [WATCH TIME: 5 minutes]

3: Insights From Child Neurology Foundation on Advancing Holistic Epilepsy Care: Jessica Nickrand, PhD; Allyson Eyermann

A duo from the Child Neurology Foundation discussed multidisciplinary collaboration, innovations in epilepsy care, and the importance of holistic, family-centric approaches to improving patient outcomes at AES 2024. [WATCH TIME: 5 minutes]

4: NeuroVoices: Barry Ticho, MD, PhD, on the Disease-Modifying Potential of STK-001 in Treating Dravet Syndrome

In our latest Q&A for NeuroVoices, the chief medical officer at Stoke Therapeutics sat down at AES 2024 to discuss the promising data behind STK-001, an investigational antisense oligonucleotide in development for Dravet syndrome.

5: Advancing Epilepsy Treatment With Novel Approaches and Predictive Technologies: Jacqueline A. French, MD

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]